MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression-Reference-Cited by-同舟云学术

MAPK‐Targeted Drug Delivered by a pH‐Sensitive MSNP Nanocarrier Synergizes with PD‐1 Blockade in Melanoma without T‐Cell Suppression

Published:2019-01-09 Issue:12 Volume:29 Page:1806916
ISSN:1616-301X
Container-title:Advanced Functional Materials
language:en
Short-container-title:Adv. Funct. Mater.

Author:

Liu Xiaowei¹,Feng Yanlin²³⁴,Xu Guangchao¹,Chen Yang¹,Luo Ya¹,Song Jinen¹,Bao Yu¹,Yang Jiqiao¹,Yu Chune¹,Li Yanna¹,Ye Haoyu¹,Ke Bowen⁴,Chen Bo⁵,Hu Jianping⁶,Xu Jie⁷,Meng Huan⁸,Zhang Haiyuan²³⁴,Shi Hubing¹

Affiliation:

1. Laboratory of Tumor Targeted and Immune TherapyClinical Research Center for BreastState Key Laboratory of BiotherapyWest China HospitalSichuan University and Collaborative Innovation Center Chengdu Sichuan 610041 China

2. Laboratory of Chemical BiologyChangchun Institute of Applied ChemistryChinese Academy of Sciences Changchun Jilin 130022 China

3. University of Science and Technology of China Hefei Anhui 230026 China

4. Laboratory of Anesthesiology and Critical Care MedicineTranslational Neuroscience Center, West China HospitalSichuan University Chengdu Sichuan 610041 China

5. Conmed Biosciences Inc. Chengdu Sichuan 61004 China

6. College of Pharmacy and Biological EngineeringChengdu University Chengdu Sichuan 610106 China

7. MOH Key Laboratory of Gastroenterology and HepatologyState Key Laboratory for Oncogenes and Related GenesRenji HospitalSchool of MedicineShanghai Jiao Tong University Shanghai 200240 China

8. Division of NanoMedicineDepartment of MedicineUniversity of California Los Angeles CA 90095 USA

Funder

National Natural Science Foundation of China

Publisher

Wiley

Subject

Electrochemistry,Condensed Matter Physics,Biomaterials,Electronic, Optical and Magnetic Materials

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/adfm.201806916

Reference70 articles.

1. Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

2. Inhibition of Mutated, Activated BRAF in Metastatic Melanoma

3. Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

4. Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation

5. Acquired Resistance and Clonal Evolution in Melanoma during BRAF Inhibitor Therapy

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Local, Sustained, and Targeted Co-Delivery of MEK Inhibitor and Doxorubicin Inhibits Tumor Progression in E-Cadherin-Positive Breast Cancer;Pharmaceutics;2024-07-25

2. Targeting hypoxic and acidic tumor microenvironment by nanoparticles: A review;Journal of Drug Delivery Science and Technology;2024-06

3. Recent progress in cancer immunotherapy: Application of nano-therapeutic systems;Journal of Drug Delivery Science and Technology;2024-01

4. Photothermally sensitive gold nanocage augments the antitumor efficiency of immune checkpoint blockade in immune “cold” tumors;Frontiers in Immunology;2023-10-24

5. Nanocarrier-based targeting of metabolic pathways for endometrial cancer: Status and future perspectives;Biomedicine & Pharmacotherapy;2023-10